BR112017028048A2 - drospirenona como o único ingrediente contraceptivo para uso - Google Patents

drospirenona como o único ingrediente contraceptivo para uso

Info

Publication number
BR112017028048A2
BR112017028048A2 BR112017028048A BR112017028048A BR112017028048A2 BR 112017028048 A2 BR112017028048 A2 BR 112017028048A2 BR 112017028048 A BR112017028048 A BR 112017028048A BR 112017028048 A BR112017028048 A BR 112017028048A BR 112017028048 A2 BR112017028048 A2 BR 112017028048A2
Authority
BR
Brazil
Prior art keywords
drospirenone
contraceptive
contraceptive ingredient
ingredient
obese
Prior art date
Application number
BR112017028048A
Other languages
English (en)
Inventor
Boyer-Joubert Cécile
Drouin Dominique
Perrin Philippe
Original Assignee
Laboratorios Leon Farma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from CN201510348953.1A external-priority patent/CN106265694A/zh
Priority claimed from EP15305965.4A external-priority patent/EP3108889A1/en
Application filed by Laboratorios Leon Farma Sa filed Critical Laboratorios Leon Farma Sa
Publication of BR112017028048A2 publication Critical patent/BR112017028048A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A61K31/585—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Reproductive Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gynecology & Obstetrics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

drospirenona como o único ingrediente contraceptivo compreendido em uma unidade de dosagem ativa diária em uma quantidade de pelo menos 3 mg para uso como um contraceptivo para uma paciente do sexo feminino afetada com obesidade.
BR112017028048A 2015-06-23 2016-06-23 drospirenona como o único ingrediente contraceptivo para uso BR112017028048A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201510348953.1A CN106265694A (zh) 2015-06-23 2015-06-23 用于过重女性患者的基于屈螺酮的避孕药
EP15305965.4A EP3108889A1 (en) 2015-06-23 2015-06-23 Drospirenone-based contraceptive for a female patient affected with excess weight
PCT/EP2016/064574 WO2016207298A1 (en) 2015-06-23 2016-06-23 Drospirenone-based contraceptive for a female patient affected with excess weight

Publications (1)

Publication Number Publication Date
BR112017028048A2 true BR112017028048A2 (pt) 2018-09-04

Family

ID=56178376

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112017028048A BR112017028048A2 (pt) 2015-06-23 2016-06-23 drospirenona como o único ingrediente contraceptivo para uso

Country Status (23)

Country Link
EP (1) EP3313408B1 (pt)
JP (1) JP6827962B2 (pt)
KR (1) KR102217942B1 (pt)
CN (2) CN113750108A (pt)
AU (1) AU2016282863B2 (pt)
BR (1) BR112017028048A2 (pt)
CA (1) CA2989975C (pt)
DK (1) DK3313408T3 (pt)
EA (1) EA036497B1 (pt)
FI (1) FI3313408T3 (pt)
HK (1) HK1255216A1 (pt)
HR (1) HRP20240121T8 (pt)
LT (1) LT3313408T (pt)
MX (1) MX2017016801A (pt)
MY (1) MY187233A (pt)
NI (1) NI201700173A (pt)
PH (1) PH12017502379A1 (pt)
PL (1) PL3313408T3 (pt)
RS (1) RS65196B1 (pt)
SI (1) SI3313408T1 (pt)
SV (1) SV2017005602A (pt)
WO (1) WO2016207298A1 (pt)
ZA (1) ZA201800067B (pt)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2383279A1 (en) 2011-07-19 2011-11-02 Pantarhei Bioscience B.V. Process for the preparation of estetrol
PL3310333T3 (pl) 2015-06-18 2020-07-13 Estetra Sprl Ulegająca rozpadowi w jamie ustnej jednostka dawkowana zawierająca składnik estetrolowy
ES2877186T3 (es) 2015-06-18 2021-11-16 Estetra Sprl Comprimido orodispersable que contiene estetrol
ES2877476T3 (es) 2015-06-18 2021-11-16 Estetra Sprl Comprimido orodispersable que contiene estetrol
PL3106148T3 (pl) 2015-06-18 2018-08-31 Mithra Pharmaceuticals S A Jednostka dawkowania ulegająca rozpadowi w jamie ustnej zawierająca składnik estetrolowy
KR20220144885A (ko) 2016-08-05 2022-10-27 에스테트라, 소시에떼 아 레스폰서빌리떼 리미떼 월경통 및 생리통의 관리방법
JOP20200260A1 (ar) 2018-04-19 2019-10-19 Estetra Sprl مركبات واستخداماتها للتخفيف من الأعراض المصاحبة لانقطاع الطمث
TWI801561B (zh) 2018-04-19 2023-05-11 比利時商依思特拉私人有限責任公司 化合物及其用於緩解絕經相關症狀的用途
EP4134082A1 (en) 2021-08-12 2023-02-15 Chemo Research, S.L. Method for treating endometriosis and providing effective contraception

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2652761C2 (de) 1976-11-16 1985-11-21 Schering AG, 1000 Berlin und 4709 Bergkamen 15,16-Methylen-Spirolactone, Verfahren zu deren Herstellung und diese enthaltende Arzneimittel
DE19525017A1 (de) * 1995-06-28 1997-01-02 Schering Ag Pharmazeutisches Kombinatonspräparat, Kit und Methode zur hormonalen Kontrazeption
DE19633685C1 (de) 1996-08-12 1997-10-09 Schering Ag Verfahren zur Herstellung von Drospirenon (6beta,7beta;15 beta,16beta-Dimethyl-en-3-oxo-17alpha-pregn-4-en-21,17-carbolacton, DRSP) sowie 7alpha-(3-Hydroxy-1-propyl)-6beta,7beta;15beta, 16beta-dimethylen-5beta-androstan-3beta,5,17beta-triol (ZK 92836) und 6beta,7beta;15beta,16beta-dimethylen-5beta-hydroxy-3-oxo-17alpha-androstan-21,17-carbolacton (90965) als Zwischenprodukte des Verfahrens
UA91190C2 (ru) * 2004-04-30 2010-07-12 Шерінг Акцієнгезельшафт Контроль прорывных кровотечений при пролонгированном режиме приема гормональных контрацептивов
MY151322A (en) * 2004-04-30 2014-05-15 Bayer Ip Gmbh Management of breakthrough bleeding in extended hormonal contraceptive regimens
ITMI20042338A1 (it) 2004-12-06 2005-03-06 Ind Chimica Srl Processo per la preparazione di drospirenone
ATE403668T1 (de) 2005-07-21 2008-08-15 Bayer Schering Pharma Ag Verfahren zur herstellung von 3-oxo-pregn-4-en-21,17-carbolactonen durch die metallfreie oxidation von 17-(3-hydroxypropyl)-3,17- dihydroxyandrostanen
US8921346B2 (en) * 2010-03-16 2014-12-30 Taizhou Taifa Pharmaceuticals Co., Ltd. Preparation method of drospirenone
AR081670A1 (es) * 2010-06-29 2012-10-10 Leon Farma Sa Lab Composicion farmaceutica que comprende drospirenona y kit anticonceptivo
CN103372015A (zh) * 2012-04-19 2013-10-30 国家人口计生委科学技术研究所 包含屈螺酮或屈螺酮和雌激素的阴道环制剂

Also Published As

Publication number Publication date
MX2017016801A (es) 2018-05-11
JP2018527305A (ja) 2018-09-20
HRP20240121T1 (hr) 2024-04-12
HK1255216A1 (zh) 2019-08-09
DK3313408T3 (da) 2024-01-29
PH12017502379A1 (en) 2018-06-25
JP6827962B2 (ja) 2021-02-10
CA2989975C (en) 2021-10-12
CA2989975A1 (en) 2016-12-29
AU2016282863A1 (en) 2018-02-08
KR102217942B1 (ko) 2021-02-19
KR20180019173A (ko) 2018-02-23
CN108025014B (zh) 2021-10-22
MY187233A (en) 2021-09-13
AU2016282863B2 (en) 2021-05-27
EP3313408A1 (en) 2018-05-02
CN108025014A (zh) 2018-05-11
LT3313408T (lt) 2024-03-12
EP3313408B1 (en) 2023-12-06
SV2017005602A (es) 2018-08-14
CN113750108A (zh) 2021-12-07
FI3313408T3 (fi) 2024-01-25
PL3313408T3 (pl) 2024-04-15
WO2016207298A1 (en) 2016-12-29
ZA201800067B (en) 2019-07-31
NI201700173A (es) 2018-04-02
EA036497B1 (ru) 2020-11-17
RS65196B1 (sr) 2024-03-29
HRP20240121T8 (hr) 2024-05-10
EA201792595A1 (ru) 2018-06-29
SI3313408T1 (sl) 2024-04-30

Similar Documents

Publication Publication Date Title
BR112017028048A2 (pt) drospirenona como o único ingrediente contraceptivo para uso
BR112017014067A2 (pt) composição para tratar doenças relacionadas a il-6
MY188749A (en) Compositions comprising a combination of nivolumab and ipilimumab
MX2020010412A (es) Inhibidores de tirosina quinasa de bruton.
BR112015018087A8 (pt) composto, composição farmacêutica e uso
BR112017015310A2 (pt) uso de pgr4 como um agente anti-inflamatório
CL2015002677A1 (es) Composiciones que comprenden selenio y uso de las mismas para el tratamiento y prevención de enfermedades o condiciones asociadas con la disfunción mitocondrial.
BR112017028140A2 (pt) formulações farmacêuticas
PH12016500978A1 (en) Piperazine derivatives having multimodal activity against pain
AR095691A1 (es) FORMULACIÓN DE L-5-METILTETRAHIDROFOLATO DE CALCIO AMORFO (L-5-MTHF-Ca), PROCEDIMIENTO, USO
ZA202006377B (en) Boronic acid derivatives and therapeutic uses thereof
MX2017013636A (es) Combinacion de dosis fija resistente a la manipulacion que proporciona una liberacion rapida de dos farmacos desde diferentes particulas.
CL2019002480A1 (es) Derivados de pirazol como inhibidores de bromodominio.
NI201900004A (es) Composición vaginal comprendiendo una combinación de estrógeno y vitamina d.
BR112018009279A8 (pt) compostos de oxadiazaespiro para o tratamento de abuso de droga e adicção
PH12019501820A1 (en) Pharmaceutical compositions for combination therapy
CL2016000397A1 (es) Tratamiento contra el cáncer
MX2017013633A (es) Combinacion de dosis fija resistente a la manipulacion que proporciona una liberacion rapida de dos farmacos desde particulas.
BR112017019364A2 (pt) dispersões sólidas
CL2015003014A1 (es) Composición farmacéutica que comprende 0,5-5 mg de (11?,17?)-17-hidroxi-11-[4-(metilsulfonil)fenil]-17-(pentafluoroetil)estra-4,9-dien-3-ona; forma de dosificación oral; uso para tratar y/o prevenir una enfermedad ginecológica, tal como, fibroides en el útero, endometriosis o hemorragias menstruales excesivas.
BR112019022459A2 (pt) Agente terapêutico para câncer no sangue
CO2018004803A2 (es) Compuestos oxa-diazaspiro que tienen actividad contra el dolor
BR112019001178A2 (pt) biotinas e composição de biotina
BR112017014295A2 (pt) composição farmacêutica.
BR112018011483A2 (pt) métodos e composições farmacêuticas com estradiol vaginalmente inserido

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B12B Appeal against refusal [chapter 12.2 patent gazette]